Efficacy of Topical Palmitoylethanolamide (Levagen+) for the Management of Eczema Symptoms: A Double-Blind, Comparator-Controlled, Randomized Clinical Trial
Randomised controlled trialHumansTopical
- Design
- Randomised controlled trial
- Subjects
- 72 adults with eczema on the hands or arms enrolled. 65 completed (32 on the palmitoylethanolamide cream, 33 on the comparator).
- Dose used in the study
- A moisturising cream with 1.5% palmitoylethanolamide (Levagen+), applied twice a day, compared with the same base cream without it
- Duration
- 4 weeks
- What was measured
- Self-assessed eczema severity, the Patient-Oriented Eczema Measure, a quality of life index and an itch rating
What the authors reported
This double-blind, comparator-controlled, randomized trial found:
- Scores for redness, dryness and the total eczema measure were lower in the palmitoylethanolamide group at week 4 (p < 0.05), with less weeping and less roughness than the comparator.
- No significant difference emerged between groups in quality of life.
- No adverse events were reported.
Limits of this study
All outcomes were assessed by the participants, with no examination by a clinician. The authors name this, and the 4-week duration, as limits. Gencor Pacific, which makes Levagen+, supplied the product and the funding.
Source
PubMed 38408443 · doi:10.1159/000536670
Entry checked against the abstract on PubMed, and the article page at the publisher (Karger) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.